+

DK1436321T3 - Syntese af cyclosporinanaloger - Google Patents

Syntese af cyclosporinanaloger

Info

Publication number
DK1436321T3
DK1436321T3 DK02767027T DK02767027T DK1436321T3 DK 1436321 T3 DK1436321 T3 DK 1436321T3 DK 02767027 T DK02767027 T DK 02767027T DK 02767027 T DK02767027 T DK 02767027T DK 1436321 T3 DK1436321 T3 DK 1436321T3
Authority
DK
Denmark
Prior art keywords
isomers
isa
cyclosporine
derivatives
mixtures
Prior art date
Application number
DK02767027T
Other languages
Danish (da)
English (en)
Inventor
Randall W Yatscoff
Mark Abel
Seetharaman Jayaraman
Hans-Jurgen Mair
Jean-Michel Adam
Bruno Lohri
Selvaraj Naicker
Robert T Foster
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Application granted granted Critical
Publication of DK1436321T3 publication Critical patent/DK1436321T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Obesity (AREA)
DK02767027T 2001-10-19 2002-10-17 Syntese af cyclosporinanaloger DK1436321T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
US37059602P 2002-04-05 2002-04-05

Publications (1)

Publication Number Publication Date
DK1436321T3 true DK1436321T3 (da) 2006-11-13

Family

ID=26994746

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06013976T DK1714977T3 (da) 2001-10-19 2002-10-17 Syntese af cyclosporinanaloger
DK02767027T DK1436321T3 (da) 2001-10-19 2002-10-17 Syntese af cyclosporinanaloger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK06013976T DK1714977T3 (da) 2001-10-19 2002-10-17 Syntese af cyclosporinanaloger

Country Status (28)

Country Link
US (13) US6998385B2 (fr)
EP (2) EP1714977B1 (fr)
JP (3) JP4261355B2 (fr)
KR (2) KR100982466B1 (fr)
CN (1) CN100334106C (fr)
AT (2) ATE425178T1 (fr)
AU (2) AU2002331509B2 (fr)
BR (1) BRPI0213658A8 (fr)
CA (1) CA2461740C (fr)
CO (1) CO5580836A2 (fr)
CY (1) CY1105111T1 (fr)
DE (2) DE60231570D1 (fr)
DK (2) DK1714977T3 (fr)
ES (2) ES2326040T3 (fr)
HK (1) HK1062568A1 (fr)
HR (2) HRP20040355B1 (fr)
IL (3) IL160763A0 (fr)
MA (1) MA27293A1 (fr)
MX (1) MXPA04003625A (fr)
NO (1) NO332459B1 (fr)
NZ (1) NZ531944A (fr)
PL (2) PL210841B1 (fr)
PT (2) PT1714977E (fr)
RU (1) RU2321593C9 (fr)
SI (1) SI1436321T1 (fr)
TN (1) TNSN04068A1 (fr)
WO (1) WO2003033526A2 (fr)
ZA (1) ZA200402269B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
PT1714977E (pt) * 2001-10-19 2009-06-23 Isotechnika Inc Síntese de análogos de ciclosporina
NZ531945A (en) * 2001-10-19 2006-01-27 Isotechnika Inc Cyclosporine analogue mixtures and their use as immunomodulating agents
JP2006524232A (ja) * 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
US20040266669A1 (en) * 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
US7799756B2 (en) 2004-07-29 2010-09-21 Albany Molecular Research, Inc. Processes for stereoselective synthesis of trans ISATX247
EP1804823A4 (fr) * 2004-09-29 2010-06-09 Amr Technology Inc Nouveaux analogues de la cyclosporine et leurs utilisations pharmaceutiques
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
JP2008515886A (ja) * 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
WO2006063470A1 (fr) * 2004-12-17 2006-06-22 Isotechnika Inc. Metabolites d'analogues de la cyclosporine
WO2007028030A2 (fr) * 2005-09-02 2007-03-08 Picobella, Llc Arn regulateurs oncogenes pour le diagnostic et la therapie
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US20070232532A1 (en) * 2006-03-28 2007-10-04 Amr Technology, Inc. Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
CN101918019B (zh) * 2007-10-08 2014-11-26 奥里尼亚制药有限公司 包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
EP2151450A1 (fr) * 2008-07-29 2010-02-10 Sandoz AG Procédé de préparation d'oligopeptides cycliques microbiologiques
CN102164948A (zh) * 2008-07-30 2011-08-24 伊索技术制药公司 非免疫抑制的环孢菌素类似分子
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
JP5406943B2 (ja) 2009-01-30 2014-02-05 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎感染を予防または治療するためのシクロスポリンアナログ
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2010144194A1 (fr) 2009-06-09 2010-12-16 Lux Biosciences, Inc. Systèmes d'administration de médicament topique pour une utilisation ophtalmique
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
KR20190002731A (ko) * 2010-12-15 2019-01-08 콘트라빌 파마슈티컬스, 인코퍼레이티드 아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자
WO2012103520A1 (fr) * 2011-01-28 2012-08-02 Board Of Regents Of The University Of Nebraska Procédés et compositions pour moduler la cyclophiline d
US10429712B2 (en) 2012-04-20 2019-10-01 View, Inc. Angled bus bar
WO2012145427A1 (fr) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Méthodes de traitement du cancer à l'aide de cyclosporine et de dérivés de cyclosporine
EP2701737B8 (fr) 2011-04-29 2024-05-01 Cartesian Therapeutics, Inc. Nanosupports synthétiques tolérogènes pour thérapie d'une allergie
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
EP2705856A1 (fr) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Composés pour le traitement de troubles neurodégénératifs
WO2014085623A1 (fr) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Nouveaux analogues de [n-me-4-hydroxyleucine]-9-cyclosporine
EP2981248B1 (fr) 2013-04-01 2020-09-02 Allergan, Inc. Dispositif d'administration de médicament par microsphère pour libération intraoculaire prolongée
EP3763359A1 (fr) 2013-05-03 2021-01-13 Selecta Biosciences, Inc. Procédé et compositions pour augmenter les cellules t régulatrices cd4+
RU2019101249A (ru) 2013-06-18 2019-03-05 Вью, Инк. Электрохромные устройства непрямоугольных форм
RU2016110247A (ru) 2013-08-26 2017-10-02 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения гепатита с
CA2957793A1 (fr) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Procedes et compositions pour attenuer des reponses immunitaires contre des vecteurs de transfert viraux pour l'edition genique
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
EP3233865A4 (fr) * 2014-12-17 2018-12-05 Verrica Pharmaceuticals, Inc. Synthèse commercialement viable de la cantharidine et de dérivés bioactifs de la cantharidine
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物
CN106554392B (zh) * 2016-11-21 2019-10-25 石家庄中天生物技术有限责任公司 一种高纯度环孢菌素衍生物stg-175的制备方法
KR20250011715A (ko) 2017-03-11 2025-01-21 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3634370A4 (fr) 2017-06-06 2021-03-03 Verrica Pharmaceuticals, Inc. Traitement des troubles cutanés
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
BR112020006703A2 (pt) 2017-10-04 2020-10-06 Verrica Pharmaceuticals, Inc. síntese de cantaridina
WO2020082061A1 (fr) 2018-10-19 2020-04-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de la voclosporine
EP4201952A1 (fr) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Procédé de synthèse contrôlée de voclosporine

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525590A (en) * 1894-09-04 canda
US4210581A (en) * 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (fr) 1975-11-04 1979-12-28 Sandoz Ag
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DK25877A (da) 1977-01-21 1978-08-15 Nordisk Insulinlab Fremgangsmaade til udvinding af renset albumin fra blodplasma
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
CH628022A5 (en) 1977-05-10 1982-02-15 Sandoz Ag Process for the preparation of an antibiotic derivative
CH630061A5 (en) 1977-05-10 1982-05-28 Sandoz Ag Process for the preparation of an antibiotic derivative
CH630062A5 (en) 1977-05-23 1982-05-28 Sandoz Ag Process for the preparation of an antibiotic derivative
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en) * 1979-03-12 1980-05-06 Merck & Co., Inc. Antibiotic A43F
AU548156B2 (en) 1980-02-14 1985-11-28 Novartis Ag Cyclo sporin
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
FR2487198A1 (fr) * 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
US4304641A (en) 1980-11-24 1981-12-08 International Business Machines Corporation Rotary electroplating cell with controlled current distribution
US4384996A (en) 1981-01-09 1983-05-24 Sandoz Ltd. Novel cyclosporins
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4727018A (en) * 1984-05-18 1988-02-23 Eichner Ronald D Immunoregulation of transplantable tissue
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8422253D0 (en) * 1984-09-04 1984-10-10 Sandoz Ltd Organic compounds
US5169773A (en) 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
CY1915A (en) 1984-10-04 1985-09-27 Sandoz Ag Cyclosporins
EP0194972B1 (fr) 1985-03-11 1992-07-29 Sandoz Ag Cyclosporines
US5047512A (en) * 1985-05-03 1991-09-10 Handschumacher Robert E Immobilized cyclophilin and methods of using such
DE3531597A1 (de) 1985-09-04 1987-03-05 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
CH670644A5 (fr) * 1986-12-18 1989-06-30 Lonza Ag
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
US4963683A (en) * 1986-12-18 1990-10-16 Sri International Process for preparing polyoxa tetracyclic compounds
NL194638C (nl) 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
US5084441A (en) * 1987-03-04 1992-01-28 Shaw Jack M Acetylated low density lipoproteins: a delivery system to phagocytic cells for stimulating immunologic response and host resistance
EP0283801A3 (fr) 1987-03-27 1990-05-30 Abbott Laboratories Essais de polarisation par fluorescence pour cyclosporine A et les métabolites et immunogènes et anticorps apparentés
US5239057A (en) * 1987-03-27 1993-08-24 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US5427960A (en) * 1987-03-27 1995-06-27 Abbott Laboratories Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ATE95193T1 (de) * 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
EP0296123B1 (fr) * 1987-06-19 1994-08-31 Sandoz Ag Peptolides cycliques
EP0373260B1 (fr) * 1987-06-22 1994-03-09 Merck & Co. Inc. Dérivés de cyclosporine avec un acide aminé modifié en position 8
GB2206119B (en) 1987-06-22 1990-10-31 Merck & Co Inc A new cyclosporin derivative with modified "8-amino acid"
GB8717299D0 (en) * 1987-07-22 1987-08-26 Nat Res Dev Peptides
GB8717300D0 (en) * 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
US5227467A (en) * 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
GB2207678A (en) 1987-08-03 1989-02-08 Merck & Co Inc Novel immunosuppressive fluorinated cyclosporin analogs
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
KR920003601B1 (ko) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US5089390A (en) * 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US4868157A (en) * 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4866036A (en) * 1987-10-05 1989-09-12 Merck & Co., Inc. Dipeptidyl 5-0,6-0-acyl-2-amino-2-deoxy-D-glucofuranose compositions and methods of use in aids-immunocompromised human hosts
US4868155A (en) * 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US4914188A (en) * 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
US5693760A (en) 1988-04-14 1997-12-02 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using HL-60 related lectins
AU614372B2 (en) * 1988-04-21 1991-08-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Novel vitamin d analogues
JPH0774799B2 (ja) 1988-04-28 1995-08-09 積水化学工業株式会社 血中成分の測定法
JP3038339B2 (ja) 1988-05-02 2000-05-08 ザイナクシス・テクノロジーズ・インコーポレーテッド バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
US5013719A (en) * 1988-05-13 1991-05-07 Merrell Dow Pharmaceuticals Inc. Method of effecting immunosuppression
DE3927804A1 (de) 1988-08-24 1990-03-01 Boehringer Ingelheim Kg Verwendung von paf-antagonisten zur behandlung von autoimmunerkrankungen
US5219884A (en) 1988-09-14 1993-06-15 Taito Co., Ltd. Immunosuppressant
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
JPH02124100A (ja) 1988-11-02 1990-05-11 Tonen Corp プロリルイソメラーゼの使用方法
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5698448A (en) 1988-12-02 1997-12-16 Soldin; Steven J. Immunosuppressive drug binding proteins and use
AU630901B2 (en) 1988-12-02 1992-11-12 Children's Research Institute Cyclosporine binding protein and use in an assay for biologically-active cyclosporine
JPH04502328A (ja) 1988-12-05 1992-04-23 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク シクロスポリンａの新規誘導体、それに対する抗体及びその使用
EP0372541A1 (fr) 1988-12-09 1990-06-13 G.D. Searle & Co. Procédé pour impartir l'immunosupression
US5153327A (en) 1988-12-23 1992-10-06 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
GB2227244A (en) 1989-01-19 1990-07-25 Merck & Co Inc Immunosuppressive fluorinated cyclosporin analogs
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5401731A (en) * 1989-06-29 1995-03-28 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Productionsaktieselskab) Vitamin D analogues
EP0410176A1 (fr) 1989-07-07 1991-01-30 Yoshitomi Pharmaceutical Industries, Ltd. Composés dérivés de l'acide amino-2 pentanoique et leur application comme immunosuppresseurs
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
GB8916901D0 (en) 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
CS277471B6 (cs) 1989-11-16 1993-03-17 Alexandr Rndr Csc Jegorov Deriváty cyklosporinu A
CS277472B6 (cs) 1989-11-16 1993-03-17 Alexandr Rndr Csc Jegorov Způsob výroby derivátů cyklosporinu A
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5591623A (en) * 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5129884A (en) * 1990-01-16 1992-07-14 Dysarz Edward D Trap in barrel one handed retracted intervenous catheter device
US5270419A (en) 1990-01-19 1993-12-14 Nova Pharmaceutical Corporation Polyanhydrides of oligomerized unsaturated aliphatic acids
US5171812A (en) 1990-01-19 1992-12-15 Nova Pharmaceutical Corporation Polyanhydrides of oligomerized unsaturated aliphatic acids
US5214130A (en) * 1990-02-27 1993-05-25 Merck & Co., Inc. Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
DE4013910A1 (de) 1990-04-26 1991-10-31 Schering Ag Kombinationspraeparat zur immunsuppressiven therapie
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
ATE132504T1 (de) * 1990-08-15 1996-01-15 Abbott Lab Immunotestreagenzien und verfahren zur bestimmung von cyclosporin
GB9017890D0 (en) * 1990-08-15 1990-09-26 Leo Pharm Prod Ltd Chemical compounds i
WO1992004055A1 (fr) 1990-09-06 1992-03-19 The Australian National University Composition immunosuppressive
CZ280909B6 (cs) * 1990-11-02 1996-05-15 Novartis Ag Nové cyklosporiny
CA2055813A1 (fr) 1990-11-20 1992-05-21 Dariush Davalian Dosage immunologique de la cyclosporine
EP0507968B1 (fr) 1991-04-06 1995-09-06 Arzneimittelwerk Dresden Gmbh Procédé de production par fermentation et isolement de cyclosporine A ainsi que de nouvelles souches productrices de cyclosporine
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
GB9116470D0 (en) 1991-07-30 1991-09-11 Erba Carlo Spa 2-(imidazol-1-yl)-benzylethylidene-aminoxyalkanoic acid derivatives
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
WO1993003729A1 (fr) 1991-08-12 1993-03-04 Research Corporation Technologies, Inc. Phenoxazines n-substituees utilisees dans le traitement de cellules cancereuses resistant a de multiples medicaments
US5972630A (en) 1991-08-19 1999-10-26 Dade Behring Marburg Gmbh Homogeneous immunoassays using enzyme inhibitors
US5217586A (en) 1992-01-09 1993-06-08 International Business Machines Corporation Electrochemical tool for uniform metal removal during electropolishing
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
GB9206648D0 (en) * 1992-03-26 1992-05-06 Leo Pharm Prod Ltd Chemical compounds
US5637317A (en) * 1992-05-18 1997-06-10 Dietl; Hans Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same
DE59310166D1 (de) 1992-05-18 2001-05-31 Ciclomulsion Ag Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
HU213553B (en) * 1992-05-25 1997-07-28 Biogal Gyogyszergyar Process for isolating of cyclosporin-a
AU4400593A (en) 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
CA2138542A1 (fr) * 1992-06-23 1994-01-06 Masaaki Ishizuka Nouveaux antibiotiques possedant une action immuno-suppressive, delamynomycines et leur mode de production
GB9214202D0 (en) * 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
EP0578616A3 (en) 1992-07-09 1994-06-01 Sandoz Ltd Cylosporin synthetase
SK277092A3 (en) 1992-09-07 1996-08-07 Galena As Medicaments with n-methylated cyclic undecapeptides
GB9220439D0 (en) 1992-09-28 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
US5318895A (en) 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
US5298523A (en) * 1992-12-14 1994-03-29 Harbor Branch Oceanographic Institution, Inc. Method for treating transplant patients using mycalamide compounds
GB9226877D0 (en) * 1992-12-23 1993-02-17 Leo Pharm Prod Ltd Chemical compounds
CA2086267A1 (fr) 1992-12-24 1994-06-25 Argyrios Margaritis Derives et conjugues derives de la cyclosporine
FI92334C (fi) * 1992-12-30 1994-10-25 Leiras Oy Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
US5393669A (en) * 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
EP0804561B1 (fr) * 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Transcription regulee de genes cibles et d'autres evenements biologiques
PT693924E (pt) * 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5468772A (en) 1993-03-10 1995-11-21 Pharmagenesis, Inc. Tripterinin compound and method
EP0697881B2 (fr) 1993-04-20 2009-05-06 Novartis AG Nouvelles compositions pharmaceutiques pour administration orale contenant de la cyclosporine
JPH08509368A (ja) 1993-04-23 1996-10-08 サンド・リミテッド 組換えアラニンラセマーゼおよびトリポクラジウム・ニベウムからのｇａｐｄｈ
AU674233B2 (en) * 1993-05-04 1996-12-12 Merck & Co., Inc. Cyclohexapeptidyl aminoalkyl ethers
DE4338086A1 (de) 1993-11-08 1995-05-11 Dietl Hans Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur oralen Applikation sowie Verfahren zu ihrer Herstellung
AU7276594A (en) 1993-08-13 1995-03-14 Banyu Pharmaceutical Co., Ltd. Endothelin-antagonistic cyclopentane derivative
JP2847969B2 (ja) 1993-08-18 1999-01-20 萬有製薬株式会社 エンドセリン拮抗活性を有する複素芳香環縮合シクロペンテン誘導体
US5421987A (en) 1993-08-30 1995-06-06 Tzanavaras; George Precision high rate electroplating cell and method
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
DE10199039I2 (de) 1993-10-22 2008-08-07 Hexal Ag Ind 25 Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator
CA2186371A1 (fr) 1994-03-25 1995-10-05 Robert T. Foster Potentialisation des dihydropyridines par deuteration
JPH07278187A (ja) 1994-04-07 1995-10-24 Nippon Shinyaku Co Ltd シクロスポリン類のリン酸エステル誘導体及び医薬組成物
US5798386A (en) 1994-08-03 1998-08-25 Cell Therapeutics, Inc. Angiogenic lipid formulations
US5948693A (en) 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
US5639852A (en) * 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5567300A (en) 1994-09-02 1996-10-22 Ibm Corporation Electrochemical metal removal technique for planarization of surfaces
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
DE4433101A1 (de) 1994-09-16 1996-03-21 Bauer Kurt Heinz Prof Dr Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren
HU215966B (hu) 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
US5648376A (en) * 1995-01-19 1997-07-15 Pharmagenesis, Inc. Immunosuppressant diterpene compound
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5668734A (en) 1995-04-10 1997-09-16 The Uab Research Foundation Method for analyzing 2D transferred noesy spectra of molecules undergoing multistate conformational exchange
JPH11504028A (ja) 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
JP3934705B2 (ja) 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
US5624902A (en) * 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
DE19521974A1 (de) 1995-06-16 1996-12-19 Hexal Pharmaforschung Gmbh Pharmazeutische Zubereitung mit Cyclosporin A
CZ290754B6 (cs) 1995-07-17 2002-10-16 C-Chem Ag Cyklický peptid, způsob jeho přípravy, farmaceutická kompozice s jeho obsahem a polyanion 1-(gamma-hydroxy)-N-methylleucin-cyklosporinu
JPH0978187A (ja) 1995-09-07 1997-03-25 Daido Steel Co Ltd メッキ用快削鋼
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CA2248192A1 (fr) 1996-03-12 1997-09-18 Picower Institute For Medical Research Traitement de l'infection a vih par action sur le recepteur de la cyclophiline de cellules hotes
US5840305A (en) 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
AUPN880396A0 (en) 1996-03-21 1996-04-18 Fremantle Hospital Animal model for transplantation
DE19611094C2 (de) 1996-03-21 1999-06-17 Dresden Arzneimittel Verfahren zur Reinigung von Cyclosporin A und/oder verwandten Cyclosporinen aus einem Cyclosporin-haltigen Rohextrakt unter Anwendung chromatographischer Verfahren mit Kieselgel als Adsorbens
JPH1029979A (ja) 1996-04-12 1998-02-03 Ajinomoto Co Inc 新規ピリジン誘導体
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
US5747330A (en) * 1996-06-05 1998-05-05 Poli Industria Chimica Antibiotic producing microbe
US5709797A (en) * 1996-06-05 1998-01-20 Poli Industria Chimica S.P.A. Method of isolating cyclosporins
EP1017366A4 (fr) 1996-09-01 2006-03-22 Pharmos Corp Coprecipites solides augmentant la biodisponibilite de substances lipophiles
GB9619894D0 (en) 1996-09-24 1996-11-06 Celltech Therapeutics Ltd Pharmaceutical products
AU740111B2 (en) 1996-09-27 2001-11-01 Jagotec Ag Hyaluronic drug delivery system
DE59710904D1 (de) 1996-12-12 2003-11-27 Dds Drug Delivery Service Ges Zubereitung in form eines wahlweise wirkstoffhaltigen matrixmaterial-hilfsstoff compounds
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US5843520A (en) 1997-01-13 1998-12-01 Vanguard International Semiconductor Corporation Substrate clamp design for minimizing substrate to clamp sticking during thermal processing of thermally flowable layers
JPH10251137A (ja) 1997-03-14 1998-09-22 Advanced Sukin Res Kenkyusho:Kk 光線過敏症抑制剤
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
AU8918998A (en) 1997-08-26 1999-03-16 Wisconsin Alumni Research Foundation Non-immunosuppressive cyclosporins and their use in the prevention and treatmentof hiv infection
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
JP4261049B2 (ja) 1997-10-08 2009-04-30 アイソテクニカ インコーポレイテッド 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用
FR2772768B1 (fr) * 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
US6706691B1 (en) 1998-07-15 2004-03-16 Board Of Regents, The University Of Texas System Immunosupportive drug sparing diet
US6187152B1 (en) 1998-07-17 2001-02-13 Cutek Research, Inc. Multiple station processing chamber and method for depositing and/or removing material on a substrate
US6183611B1 (en) 1998-07-17 2001-02-06 Cutek Research, Inc. Method and apparatus for the disposal of processing fluid used to deposit and/or remove material on a substrate
FI110094B (fi) 1999-09-10 2002-11-29 Ecospec Ltd Oy Menetelmä maanparannusaineen valmistamiseksi
KR100801588B1 (ko) 1999-09-21 2008-02-05 스키에파마 캐나다 인코포레이티드 생물학적 유효 물질의 표면 변형된 미립자 조성물
WO2001028519A1 (fr) 1999-10-20 2001-04-26 Vesifact Ag Microemulsions preconcentrees et microemulsions correspondantes
WO2003004469A1 (fr) 2001-07-02 2003-01-16 Dabur Research Foundation Action anticancereuse de conjugues iminoacides de methylglyoxal
PT1714977E (pt) 2001-10-19 2009-06-23 Isotechnika Inc Síntese de análogos de ciclosporina
NZ531945A (en) 2001-10-19 2006-01-27 Isotechnika Inc Cyclosporine analogue mixtures and their use as immunomodulating agents
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン

Also Published As

Publication number Publication date
US20160075741A1 (en) 2016-03-17
DE60231570D1 (de) 2009-04-23
NO332459B1 (no) 2012-09-24
DK1714977T3 (da) 2009-07-06
JP5396571B2 (ja) 2014-01-22
KR101006206B1 (ko) 2011-01-07
US20100311944A1 (en) 2010-12-09
USRE48226E1 (en) 2020-09-29
US20170362277A1 (en) 2017-12-21
DE60213115D1 (en) 2006-08-24
NZ531944A (en) 2006-03-31
MA27293A1 (fr) 2005-05-02
JP4887469B2 (ja) 2012-02-29
US7141648B2 (en) 2006-11-28
IL186140A0 (en) 2008-01-20
US20100062976A1 (en) 2010-03-11
KR20050037417A (ko) 2005-04-21
IL160763A0 (en) 2004-08-31
BR0213658A (pt) 2004-10-26
EP1436321A2 (fr) 2004-07-14
RU2321593C2 (ru) 2008-04-10
HRP20070058B1 (hr) 2014-05-23
IL160763A (en) 2009-11-18
WO2003033526A3 (fr) 2004-02-12
ES2326040T3 (es) 2009-09-29
SI1436321T1 (sl) 2006-12-31
HRP20040355A2 (en) 2005-04-30
WO2003033526A2 (fr) 2003-04-24
EP1436321B1 (fr) 2006-07-12
KR100982466B1 (ko) 2010-09-16
US9765119B2 (en) 2017-09-19
CO5580836A2 (es) 2005-11-30
ZA200402269B (en) 2005-05-25
PL210841B1 (pl) 2012-03-30
CA2461740C (fr) 2013-02-12
JP2009046515A (ja) 2009-03-05
PL392749A1 (pl) 2011-01-03
RU2321593C9 (ru) 2008-06-20
NO20042031L (no) 2004-05-19
US20140370082A1 (en) 2014-12-18
US20030212249A1 (en) 2003-11-13
KR20090130195A (ko) 2009-12-18
HK1062568A1 (en) 2004-11-12
TNSN04068A1 (en) 2006-06-01
CY1105111T1 (el) 2010-03-03
PL370772A1 (en) 2005-05-30
US10472394B2 (en) 2019-11-12
US20140142277A1 (en) 2014-05-22
JP2010280710A (ja) 2010-12-16
EP1436321B9 (fr) 2008-11-12
ATE332917T1 (de) 2006-08-15
RU2004110940A (ru) 2005-06-27
EP1714977A2 (fr) 2006-10-25
HRP20040355B1 (hr) 2012-10-31
DE60213115T2 (de) 2007-02-01
JP4261355B2 (ja) 2009-04-30
AU2010206069A1 (en) 2010-08-19
MXPA04003625A (es) 2004-12-02
ES2266564T3 (es) 2007-03-01
US7332472B2 (en) 2008-02-19
EP1714977B1 (fr) 2009-03-11
US20070087963A1 (en) 2007-04-19
BRPI0213658A8 (pt) 2016-12-06
PL210795B1 (pl) 2012-03-30
HRP20070058A2 (en) 2008-09-30
CA2461740A1 (fr) 2003-04-24
JP2005516893A (ja) 2005-06-09
US20080171850A1 (en) 2008-07-17
PT1436321E (pt) 2006-10-31
US20050192214A1 (en) 2005-09-01
EP1714977A3 (fr) 2007-01-10
ATE425178T1 (de) 2009-03-15
PT1714977E (pt) 2009-06-23
CN100334106C (zh) 2007-08-29
CN1571795A (zh) 2005-01-26
IL186140A (en) 2012-02-29
US20030139326A1 (en) 2003-07-24
AU2002331509B2 (en) 2007-12-06
US6998385B2 (en) 2006-02-14
US20130078280A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
DK1714977T3 (da) Syntese af cyclosporinanaloger
MY187182A (en) Cyclosporine analogue mixtures and their use as immunomodulating agents
ATE334654T1 (de) Vor uv-strahlen schützende zusammensetzungen
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
ATE245435T1 (de) Totalsynthese des amino hip analogen von didemnin a
BR0202204A (pt) Formulações estabilizadas
YU33204A (sh) Sinteza analoga ciklosporina
DK1250337T3 (da) Substituerede homopiperidinylbenzimidazol-analoger som fundus-relaksanter
YU33004A (sh) Smeša analoga ciklosporina i njihova upotreba u svojstvu imunomodulatornih supstanci
BR0000850B1 (pt) mistura de 3-metiloct-6-enóis 6-substituìdos, composição adorante contendo a referida mistura, bem como seu uso.
TW374693B (en) Fungicidal mixtures
RU2003125376A (ru) Композиции, содержащие циклогексамантан
UY27523A1 (es) Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载